SIM0272 / Simcere - LARVOL DELTA

PRMT5 inhibitor SCR-6920 downregulates HIF-1α and exhibits synergistic antitumor activity with Bevacizumab (AACR 2026) - P1 | "Furthermore, SCR-6920 exhibited synergistic or additive effects when combined with several standard-of-care chemotherapies and targeted agents for solid tumors, including paclitaxel, docetaxel, doxorubicin, and olaparib. The unveiled mechanism, whereby PRMT5 inhibition promotes HIF-1α degradation, provides the foundation for the observed synergistic activity with bevacizumab. These findings position SCR-6920 as a compelling clinical candidate for solid tumors, particularly in rational combinations aimed at overcoming resistance to anti-angiogenic therapy."

Oncology • Ovarian Cancer • Solid Tumor • HIF1A

A phase I study of safety, pharmacokinetics, and pharmacodynamics of SCR-6920, a protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced malignant tumors (ESMO 2023) - P1 | "Plasma symmetric dimethyl arginine (SDMA), the enzymatic product of PRMT5 was significantly reduced (inhibitory rate: 52.8%∼77.4%) at steady state. Conclusions SCR-6920 had a manageable safety profile and further assessments are ongoing to determine the RP2Ds."

Clinical • Metastases • P1 data • PK/PD data • Cervical Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor

A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors (clinicaltrials.gov) - P1 | N=122 | Recruiting | Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.

New P1 trial • Hematological Malignancies • Lymphoma • Non Small Cell Lung Cancer • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor • PRMT5